TY - JOUR
T1 - Minimal residual disease after transplantation or lenalidomidebased consolidation in myeloma patients
T2 - A prospective analysis
AU - Oliva, Stefania
AU - Gambella, Manuela
AU - Gilestro, Milena
AU - Muccio, Vittorio Emanuele
AU - Gay, Francesca
AU - Drandi, Daniela
AU - Ferrero, Simone
AU - Passera, Roberto
AU - Pautasso, Chiara
AU - Bernardini, Annalisa
AU - Genuardi, Mariella
AU - Patriarca, Francesca
AU - Saraci, Elona
AU - Petrucci, Maria Teresa
AU - Pescosta, Norbert
AU - Liberati, Anna Marina
AU - Caravita, Tommaso
AU - Conticello, Concetta
AU - Rocci, Alberto
AU - Musto, Pellegrino
AU - Boccadoro, Mario
AU - Palumbo, Giuseppe Antonio
AU - Omedè, Paola
PY - 2017
Y1 - 2017
N2 - We analyzed 50 patients who achieved at least a very good partial response in the RV-MM-EMN-441 study. Patients received consolidation with autologous stem-cell transplantation (ASCT) or cyclophosphamide-lenalidomide-dexamethasone (CRD), followed by Lenalidomide-based maintenance. We assessed minimal residual disease (MRD) by multi-parameter flow cytometry (MFC) and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction (ASO-RQ-PCR) after consolidation, after 3 and 6 courses of maintenance, and thereafter every 6 months until progression. By MFC analysis, 19/50 patients achieved complete response (CR) after consolidation, and 7 additional patients during maintenance. A molecular marker was identified in 25/50 patients, 4/25 achieved molecular-CR after consolidation, and 3 additional patients during maintenance. A lower MRD value by MFC was found in ASCT patients compared with CRD patients (p = 0.0134). Tumor burden reduction was different in patients with high-risk vs standard-risk cytogenetics (3.4 vs 5.2, ln-MFC; 3 vs 6 ln-PCR, respectively) and in patients who relapsed vs those who did not (4 vs 5, ln-MFC; 4.4 vs 7.8 ln-PCR). MRD progression anticipated clinical relapse by a median of 9 months while biochemical relapse by a median of 4 months. MRD allows the identification of a low-risk group, independently of response, and a better characterization of the activity of treatments.
AB - We analyzed 50 patients who achieved at least a very good partial response in the RV-MM-EMN-441 study. Patients received consolidation with autologous stem-cell transplantation (ASCT) or cyclophosphamide-lenalidomide-dexamethasone (CRD), followed by Lenalidomide-based maintenance. We assessed minimal residual disease (MRD) by multi-parameter flow cytometry (MFC) and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction (ASO-RQ-PCR) after consolidation, after 3 and 6 courses of maintenance, and thereafter every 6 months until progression. By MFC analysis, 19/50 patients achieved complete response (CR) after consolidation, and 7 additional patients during maintenance. A molecular marker was identified in 25/50 patients, 4/25 achieved molecular-CR after consolidation, and 3 additional patients during maintenance. A lower MRD value by MFC was found in ASCT patients compared with CRD patients (p = 0.0134). Tumor burden reduction was different in patients with high-risk vs standard-risk cytogenetics (3.4 vs 5.2, ln-MFC; 3 vs 6 ln-PCR, respectively) and in patients who relapsed vs those who did not (4 vs 5, ln-MFC; 4.4 vs 7.8 ln-PCR). MRD progression anticipated clinical relapse by a median of 9 months while biochemical relapse by a median of 4 months. MRD allows the identification of a low-risk group, independently of response, and a better characterization of the activity of treatments.
KW - ASO-RQ-PCR
KW - Flow cytometry
KW - MRD
KW - Myeloma
KW - Novel agents
UR - http://www.scopus.com/inward/record.url?scp=85010818822&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85010818822&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.12641
DO - 10.18632/oncotarget.12641
M3 - Article
AN - SCOPUS:85010818822
VL - 8
SP - 5924
EP - 5935
JO - Oncotarget
JF - Oncotarget
SN - 1949-2553
IS - 4
ER -